4-72128735-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_004885.3(NPFFR2):āc.144C>Gā(p.Phe48Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000458 in 1,614,110 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000033 ( 0 hom., cov: 30)
Exomes š: 0.000047 ( 0 hom. )
Consequence
NPFFR2
NM_004885.3 missense
NM_004885.3 missense
Scores
2
7
10
Clinical Significance
Conservation
PhyloP100: 3.30
Genes affected
NPFFR2 (HGNC:4525): (neuropeptide FF receptor 2) This gene encodes a member of a subfamily of G-protein-coupled neuropeptide receptors. This protein is activated by the neuropeptides A-18-amide (NPAF) and F-8-amide (NPFF) and may function in pain modulation and regulation of the opioid system. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jan 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.2508083).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
NPFFR2 | NM_004885.3 | c.144C>G | p.Phe48Leu | missense_variant | 2/4 | ENST00000308744.12 | |
NPFFR2 | NM_001144756.2 | c.153C>G | p.Phe51Leu | missense_variant | 3/5 | ||
NPFFR2 | NM_053036.3 | c.144C>G | p.Phe48Leu | missense_variant | 2/4 | ||
NPFFR2 | XM_011531554.3 | c.305-9305C>G | intron_variant |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
NPFFR2 | ENST00000308744.12 | c.144C>G | p.Phe48Leu | missense_variant | 2/4 | 1 | NM_004885.3 | P4 | |
NPFFR2 | ENST00000395999.5 | c.153C>G | p.Phe51Leu | missense_variant | 3/5 | 1 | A2 | ||
NPFFR2 | ENST00000358749.3 | c.144C>G | p.Phe48Leu | missense_variant | 2/4 | 1 | P4 | ||
NPFFR2 | ENST00000344413.6 | c.-20-9305C>G | intron_variant | 1 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152166Hom.: 0 Cov.: 30
GnomAD3 genomes
AF:
AC:
5
AN:
152166
Hom.:
Cov.:
30
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000151 AC: 38AN: 251384Hom.: 0 AF XY: 0.000162 AC XY: 22AN XY: 135868
GnomAD3 exomes
AF:
AC:
38
AN:
251384
Hom.:
AF XY:
AC XY:
22
AN XY:
135868
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000472 AC: 69AN: 1461826Hom.: 0 Cov.: 31 AF XY: 0.0000633 AC XY: 46AN XY: 727204
GnomAD4 exome
AF:
AC:
69
AN:
1461826
Hom.:
Cov.:
31
AF XY:
AC XY:
46
AN XY:
727204
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000328 AC: 5AN: 152284Hom.: 0 Cov.: 30 AF XY: 0.0000672 AC XY: 5AN XY: 74448
GnomAD4 genome
AF:
AC:
5
AN:
152284
Hom.:
Cov.:
30
AF XY:
AC XY:
5
AN XY:
74448
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
19
Asia WGS
AF:
AC:
4
AN:
3478
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 14, 2023 | The c.450C>G (p.F150L) alteration is located in exon 2 (coding exon 2) of the NPFFR2 gene. This alteration results from a C to G substitution at nucleotide position 450, causing the phenylalanine (F) at amino acid position 150 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;.;.
MutationTaster
Benign
D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
D;D;D
REVEL
Benign
Sift
Benign
T;T;T
Sift4G
Benign
T;.;T
Polyphen
P;P;.
Vest4
MutPred
Loss of helix (P = 0.4763);.;.;
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at